Manhattan Scientifics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Manhattan Scientifics Inc (MHTX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Manhattan Scientifics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 48,229M combined for its competitors (0.0% combined share).
- Scale: Manhattan Scientifics Inc ranks #124 of 143 companies by market capitalization in the Industrial Machinery and Components industry, holding 0.0% of industry market cap.
- Peer differentiation: Revenue per employee of $0.01M compares with $0.42M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
API endpoints for this dataset
Manhattan Scientifics Inc vs. its Competitors, Q2 2024
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Manhattan Scientifics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Manhattan Scientifics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Manhattan Scientifics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Manhattan Scientifics Inc's competitor groups requires a Commercial License.
Manhattan Scientifics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Manhattan Scientifics Inc | - | - | - | Yes |
| Competitors combined (2) | ||||
| High-Confidence Competitors (4) | ||||
| Similar-Size Competitors (8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MHTX Stock Performance relative to its Competitors
MHTX Stock Performance relative to High-Confidence Competitors
MHTX Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Abbott Laboratories | 282.9% | Outperformed |
| 2 | Mdxhealth Sa | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Manhattan Scientifics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Manhattan Scientifics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Manhattan Scientifics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Manhattan Scientifics Inc |
0.06 | 0.14 |
 Abbott Laboratories |
188,597.56 | 48,229.00 |
 Mdxhealth Sa |
7.20 | 107.88 |
| SUBTOTAL | 188,604.81 | 48,337.02 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Manhattan Scientifics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Manhattan Scientifics Inc's Competitors Named by the Company
Competitive relationships identified from Manhattan Scientifics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Cepheid Inc. | Company report | 85% |
| Abbott Laboratories Inc. | Company report | 85% |
| MDxHealth SA | Company report | 85% |
| Sequenom, Inc. | Company report | 85% |
| Philips | Company report | 85% |
| Gen-Probe Incorporated | Company report | 85% |
| Siemens | Company report | 85% |
| EpiGenomics AG | Company report | 85% |
| Roche Diagnostics | Company report | 85% |
| GE Healthcare | Company report | 85% |
Company report basis, confidence, active dates and source counts for Manhattan Scientifics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Manhattan Scientifics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Abbott Laboratories | Diabetes Care 16.79 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Manhattan Scientifics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Manhattan Scientifics Inc | 0 | 12,909 | -96,000 |
| Abbott Laboratories | 188,598 | 419,383 | 40,878 |
| Mdxhealth Sa | 7 | 534,035 | -165,936 |
| PEERS TOTAL | 188,605 | 419,584 | 40,516 |
Manhattan Scientifics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Abbott Laboratories | Non-US 57.70 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Manhattan Scientifics Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 127 companies in Manhattan Scientifics Inc's industry classification, broader than the peer set above. Market cap in millions of $.Manhattan Scientifics Inc ranks #124 of 127 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,564, indicating a moderately concentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Asml Holding Nv | 581,468 | 32.87 % |
| 2 | Lam Research Corporation | 284,908 | 16.10 % |
| 3 | Deere and Co | 182,327 | 10.31 % |
| 4 | Eaton Corporation Plc | 137,482 | 7.77 % |
| 5 | Illinois Tool Works Inc | 1,234 | 5.2% |
| 6 | Bloom Energy Corporation | 1,234 | 5.2% |
| 7 | Carrier Global Corporation | 1,234 | 5.2% |
| 8 | Ingersoll Rand Inc | 1,234 | 5.2% |
| 9 | Dover Corp | 1,234 | 5.2% |
| 10 | Woodward Inc | 1,234 | 5.2% |
| 124 | Manhattan Scientifics Inc | 0 | 0.00 % |
Market cap and industry share for the rest of Manhattan Scientifics Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-12.
Manhattan Scientifics Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 119 | Originclear Inc | 2 | - |
| 120 | Nauticus Robotics Inc | 1 | -89.55 % |
| 121 | Nuburu Inc | 1 | -81.64 % |
| 122 | U Power Limited | 1,234 | 12.3% |
| 123 | Li Bang International Corporation Inc | 1,234 | 12.3% |
| 124 | Manhattan Scientifics Inc | 0 | - |
| 125 | Peregrine Industries Inc | 1,234 | 12.3% |
| 126 | Reto Eco Solutions Inc | 1,234 | 12.3% |
| 127 | Advent Technologies Holdings Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Manhattan Scientifics Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-13. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Manhattan Scientifics Inc's Valuation vs Competitive Position
Valuation multiples vs the Industrial Machinery and Components industry average (177 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Industrial Machinery and Components industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 33.9x | - |
| EV / EBITDA | 0.8x | 17.0x | -16.2x |
| P/B | -0.3x | 3.9x | -4.2x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -0.66 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Manhattan Scientifics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | - | - | - |
| Operating Margin | - | -1,604.23 % | - | - | - | - | - | - |
| Return on Invested Capital | -56.92 % | -11.46 % | -19.69 % | - | -55.24 % | -12.53 % | - | - |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Manhattan Scientifics Inc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Manhattan Scientifics Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 7.5% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Manhattan Scientifics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 1,564 (see Industry Market Structure & Concentration above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Manhattan Scientifics Inc's dedicated Suppliers and Customers pages, not here.
Manhattan Scientifics Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Manhattan Scientifics Inc falls in the Medium attractiveness / Low strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Manhattan Scientifics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-13.9% annualized).
Methodology: see Methodology: SWOT Analysis.
Manhattan Scientifics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Manhattan Scientifics Inc | - | 0.03 | - |
| Abbott Laboratories | 0.36 | 1.45 | 0.53 |
| Mdxhealth Sa | 0.59 | 1.08 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Manhattan Scientifics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Manhattan Scientifics Inc | Q2 2024 | - | - |
| Abbott Laboratories | Q3 2026 | +14.5 % | -44.0 % |
| Mdxhealth Sa | Q4 2025 | +19.8 % | - |
| PEERS TOTAL | +14.5 % | -44.8 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Manhattan Scientifics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Manhattan Scientifics Inc | Q2 2024 | - | - |
| Abbott Laboratories | Q3 2026 | +10.9 % | +3.4 % |
| Mdxhealth Sa | Q4 2025 | +9.6 % | -2.6 % |
Manhattan Scientifics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Manhattan Scientifics Inc | - | - | - |
| Abbott Laboratories | 4.54% | 5.14% | 9.00% |
| Mdxhealth Sa | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Manhattan Scientifics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Manhattan Scientifics Inc | - | 0.39 |
| Abbott Laboratories | 40.19 | 3.91 |
| Mdxhealth Sa | - | 0.07 |
| PEERS AVERAGE | 40.42 | 3.90 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.